Literature DB >> 20937314

Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue.

Soledad Mac Keon1, Silvina Gazzaniga, Julieta Mallerman, Alicia I Bravo, José Mordoh, Rosa Wainstok.   

Abstract

Antigen presentation by dendritic cells (DC) is of key importance for the initiation of the primary immune response. Mice vaccinated with DC charged with apoptotic/necrotic B16 cells (DC-Apo/Nec) are protected against B16 challenge. The aim of this study was to assess vaccine cell migration in our system and to find out if there is an immunological response taking place at the vaccination site. The formation of a pseudocapsule, peripheral node addresin expression in small venules, and the recruitment of a wide variety of cellular populations, including macrophages, polymorphonuclear lymphocytes, and CD8+ and CD4+ T lymphocytes found in association with DC, evidenced the formation of tertiary lymphoid tissue in the vaccination site in our experimental system.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20937314     DOI: 10.1016/j.vaccine.2010.09.095

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Cell and tissue engineering in lymph nodes for cancer immunotherapy.

Authors:  Alexander J Najibi; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2020-08-01       Impact factor: 15.470

2.  Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells.

Authors:  María Marcela Barrio; Riad Abes; Marina Colombo; Gabriela Pizzurro; Charlotte Boix; María Paula Roberti; Emmanuelle Gélizé; Mariana Rodriguez-Zubieta; José Mordoh; Jean-Luc Teillaud
Journal:  PLoS One       Date:  2012-07-02       Impact factor: 3.240

Review 3.  Dendritic cell-based vaccine efficacy: aiming for hot spots.

Authors:  Gabriela Andrea Pizzurro; María Marcela Barrio
Journal:  Front Immunol       Date:  2015-03-03       Impact factor: 7.561

Review 4.  Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models.

Authors:  Soledad Mac Keon; María Sol Ruiz; Silvina Gazzaniga; Rosa Wainstok
Journal:  Front Immunol       Date:  2015-05-20       Impact factor: 7.561

5.  Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice.

Authors:  Andrés H Rossi; Ana Farias; Javier E Fernández; Hernán R Bonomi; Fernando A Goldbaum; Paula M Berguer
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

Review 6.  Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.

Authors:  Florencia Paula Madorsky Rowdo; Antonela Baron; Mariela Urrutia; José Mordoh
Journal:  Front Immunol       Date:  2015-03-26       Impact factor: 7.561

7.  Inoculation site from a cutaneous melanoma patient treated with an allogeneic therapeutic vaccine: a case report.

Authors:  Mariana Aris; Alicia Inés Bravo; María Marcela Barrio; José Mordoh
Journal:  Front Immunol       Date:  2015-03-30       Impact factor: 7.561

Review 8.  Therapeutic use of dendritic cells to promote the extranodal priming of anti-tumor immunity.

Authors:  Lu Chen; Kellsye L Fabian; Jennifer L Taylor; Walter J Storkus
Journal:  Front Immunol       Date:  2013-11-29       Impact factor: 7.561

9.  Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro Analysis of Immune Recruitment and Cytokine Release.

Authors:  María B Pampena; María M Barrio; Estefanía P Juliá; Paula A Blanco; Erika M von Euw; José Mordoh; Estrella Mariel Levy
Journal:  Front Immunol       Date:  2017-10-23       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.